Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGF2 | P09038 | 1/20 | 0.45 |
| ▸ | M6PR | P20645 | 2/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | IDUA | P35475 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HPSE | Q9Y251 | 2/20 | 0.39 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.39 |
| ▸ | G6PD | P11413 | 1/20 | 0.37 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.37 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL850007 | 1.00 | FGF2 (0.45) | FGF2M6PRAKT1IDUAKDM4E | |
| SCHEMBL18067350 | 1.00 | FGF2 (0.45) | FGF2M6PRAKT1IDUAKDM4E | |
| SCHEMBL18030805 | 1.00 | FGF2 (0.45) | FGF2M6PRAKT1IDUAKDM4E | |
| SCHEMBL13523545 | 1.00 | FGF2 (0.45) | FGF2M6PRAKT1IDUAKDM4E | |
| SCHEMBL24212702 | 1.00 | FGF2 (0.45) | FGF2M6PRAKT1IDUAKDM4E | |
| SCHEMBL7152405 | 1.00 | FGF2 (0.45) | FGF2M6PRAKT1IDUAKDM4E | |
| SCHEMBL23343942 | 1.00 | FGF2 (0.45) | FGF2M6PRAKT1IDUAKDM4E | |
| SCHEMBL13478949 | 1.00 | FGF2 (0.45) | FGF2M6PRAKT1IDUAKDM4E | |
| SCHEMBL21134565 | 1.00 | FGF2 (0.45) | FGF2M6PRAKT1IDUAKDM4E | |
| SCHEMBL21586585 | 1.00 | FGF2 (0.45) | FGF2M6PRAKT1IDUAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9592240-B2 | Targeted pyrrolobenzodiazapine conjugates | SEATTLE GENETICS INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-8785416-B2 | Sulphated disaccharides for the treatment of neurodegenerative and/or neurovascular diseases | BIOIBERICA, S.A. (ES) | 2014-07-22 | — | — | US | disclosed |
| US-20120309707-A1 | SULPHATED DISACCHARIDES FOR THE TREATMENT OF NEURODEGENERATIVE AND/OR NEUROVASCULAR DISEASES | UNIVERSIDAD AUTONOMA DE MADRID (ES) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309707-A1 | SULPHATED DISACCHARIDES FOR THE TREATMENT OF NEURODEGENERATIVE AND/OR NEUROVASCULAR DISEASES | GALC, SMN1; SMN2, SORD | FGF2 358/4885M6PR 591/4885AKT1 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.